Mathers Edward T 4
4 · MBX Biosciences, Inc. · Filed Jun 5, 2026
Research Summary
AI-generated summary of this filing
MBX Biosciences Director Edward T. Mathers Receives 12,500-Share Award
What Happened
- Edward T. Mathers, a director of MBX Biosciences (MBX), was granted 12,500 derivative shares on June 4, 2026. The award was reported on a Form 4 filed June 5, 2026. The grant price is $0.00, so the reported acquisition value is $0. This is a compensation-related award (not an open-market purchase or sale).
Key Details
- Transaction date: 2026-06-04; Form 4 filed: 2026-06-05 (timely).
- Transaction type: Award/other acquisition (Form 4 code A); derivative security.
- Amount and price: 12,500 shares acquired at $0.00 per share; reported value $0.
- Vesting: The grant vests in full on the earlier of the one-year anniversary of the grant date or the date of the next annual meeting of stockholders, subject to the director’s continued service (footnote F1).
- Shares owned after transaction: Not specified in the filing.
- Accession: 0001193125-26-259236 (for reference).
Context
- This appears to be a routine non-employee director compensation award (likely RSUs or a similar derivative) with a short vesting schedule; such awards are common and reflect compensation, not necessarily an insider buying or selling on personal conviction.
Insider Transaction Report
Form 4
Mathers Edward T
Director
Transactions
- Award
Stock option (right to buy)
[F1]2026-06-04+12,500→ 12,500 totalExercise: $30.91Exp: 2036-06-04→ Common Stock (12,500 underlying)
Footnotes (1)
- [F1]The grant will vest in full on the earlier of the one-year anniversary of the grant date or on the date of our next annual meeting of stockholders, subject to the non-employee director's continued services to the Company.
Signature
/s/ Zachary Bambach, attorney-in-fact|2026-06-05